H1 2024 revenue fell 32% and net profit dropped 67% year-over-year, mainly due to lower respiratory product demand, while R&D investment and international expansion continued. Cardiovascular and respiratory products remain market leaders despite industry headwinds.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.